GRFSGrifols, S.A.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−9% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −9% vs its 200-day average.
Lightly shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GRFS is trading
Grifols, S.A. is −24% over the past year while the S&P 500 is +18%: 42 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −9.3%
vs 200-day average · below trend, but not far
- RSI (14)
- 55
RSI (14) · neutral
- Below its 52-week high
- 26%
Below its 52-week high
Details›
- Last close2026-10-09
- $7.45
- 1 monthS&P 500 +2.7%
- −2.5%
- 1 yearS&P 500 +18%
- −24%
- 5 yearsS&P 500 +88%
- −47%
- vs 50-day average$7.67
- −2.9%
- 52-week high
- $10.02
- 52-week low
- $7.00
- Annualised volatility
- 38%
| Year | Return |
|---|---|
| 2026 (year to date) | −20% |
| 2025 | +28% |
| 2024 | −36% |
| 2023 | +36% |
| 2022 | −24% |
| 2021 | −37% |
| 2020 | −20% |
| 2019 | +29% |
| 2018 | −18% |
| 2017 | +45% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | −1.8% |
| Feb | 10 | 4 of 10 | −0.56% |
| Mar | 10 | 3 of 10 | −4.9% |
| Apr | 10 | 5 of 10 | −0.13% |
| May | 10 | 5 of 10 | +4.8% |
| Jun | 10 | 4 of 10 | +1.2% |
| Jul | 11 | 7 of 11 | +3.2% |
| Aug | 11 | 2 of 11 | −3.5% |
| Sep | 11 | 4 of 11 | −2.5% |
| Oct | 11 | 4 of 11 | −2.2% |
| Nov | 10 | 5 of 10 | +2.2% |
| Dec | 10 | 8 of 10 | +4.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
Ranks #6 of 7 by RyuScore